Search the Site
Print


BioRunUp has evolved into an informed Biotech trading community seeking to generate consistent profits (in any market condition) through a variety of long, short and options based strategies.


Take a look at our recent verified profits of over $500,000
Mark Messier
Mike Havrilla

Join Our FREE Mailing List and Receive the eBook
"Five Tips to Better Biotech Trading / 
Understanding the BioCatalyst Process"
Some of the features of the new BioRunUp.com include:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database- over 300 events and updated daily 
- Members Only Live Interactive Webinars 
- Live Chat Room 
- Video Lessons / Trade Reviews
- Chart / Technical Analysis 
- BioRunUp Forums
- Run-Up Valuation Studies
- Weekly Watchlist Newsletter
- Email / SMS (Text Message) Alerts of critical news
- Screenshots of BioRunUp (Mark Messier) and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Historical FDA Tracker
- Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates
- Direct Email Communication
- Affiliate Program

The cost for an annual subscription is $497 and includes all the above features. We also offer a monthly plan for $79.95. 


Take a look at excerpts from BioRunUp subscriber testimonials:

"My most recent and profitable trade are the EXAS Oct $5 options which I purchased at $.40 off of BioRunUp blog alert. They are currently yielding a 700% return!!!"

"Within 1 month my brand new porfolio was up over 23%!"

"I started the biorunup method on Aug. 9th 2010 and before the end of Sept. I was up 35%."

"In the first month I made a 13% return, doubling the return of the market as a whole - without leverage. To date, I have never failed to beat the market when applying the methods outlined in the pages of BioRunUp."

"
I don’t ever take recommendations from people on the Internet, but this one looked right, felt right and sounded right.  Thanks BioRunUp, you made me a fortune."

 

Recent articles

  $TSRX Reports Positive Results in First of Two Phase 3 Trials for Antibiotic Drug (in: Articles)
Jan 26, 2012
Written by Mike Havrilla--Trius Therapeutics (NASDAQ:TSRX) is focused on the development of antibiotics for life-threatening infections with a summary of the Company's late-stage product candidate below.
  Webinar - Thursday January 26th at 4:30pm EST (in: Articles)
Jan 25, 2012
  $KOOL Cites Global Economic Crisis, Increased Competition for Weak Results (in: Articles)
Jan 24, 2012
Written by Mike Havrilla -- ThermoGenesis (NASDAQ:KOOL) is a regenerative medicine company focused on the development and commercialization of products and devices for the collection, processing, and storage of adult stem cells derived from the bone marrow and cord blood sources, in addition to other blood-based components such as fibrin and platelets.
  AMRN Chart Analysis - Video (in: Articles)
Jan 23, 2012
  AMLN FDA Pre-Decision Options Trading Plan (in: Articles)
Jan 23, 2012
  This Week's Watchlist 1/23/12 (in: Articles)
Jan 22, 2012
  This Week's Catalyst Calendar Summary - 1/21/12 (in: Articles)
Jan 21, 2012
  $TZYM Extends $BMY Pact, Expects Initial Phase 3 Results in Spring 2012 (in: Articles)
Jan 20, 2012
Written by Mike Havrilla -- Tranzyme Pharma (NASDAQ:TZYM) is a biopharmaceutical company focused on the development of new drugs for the treatment of chronic GI (gastrointestinal) motility disorder based on its MATCH drug discovery technology platform.
  $KERX Stock Chart Analysis (in: Articles)
Jan 19, 2012
  $CRMD Spec Bio Stock with Insider Buying and CE Mark Catalyst (in: Articles)
Jan 18, 2012
Written by Mike Havrilla--CorMedix (NYSEAMEX:CRMD) is focused on the development of lead product candidate NEUTROLIN
  This Week's Watchlist 1/17/12 (in: Articles)
Jan 16, 2012
  This Weeks Catalyst Calendar Summary 1/13/12 (in: Articles)
Jan 14, 2012
  $CRIS Stock Chart Analysis (in: Articles)
Jan 13, 2012
  1/10/12 Webinar On-Demand (in: Articles)
Jan 12, 2012
  $AMRN Stock Chart Analysis (in: Articles)
Jan 11, 2012
  $YMI CYT387 Is Key Value Driver with Multiple Catalysts Expected in 2012 (in: Articles)
Jan 11, 2012
Written by Mike Havrilla--YM BioSciences (NYSEAMEX:YMI) is a small-cap biopharmaceutical company with three products currently in clinical development, including CYT387 (a small molecule dual inhibitor of the JAK1/JAK2 kinases), nimotuzumab (an EGFR-targeting monoclonal antibody), and CYT997 (a vascular disrupting agent or VDA).
  $ASTX Cancer Biotech Trading Near Cash with Pending FDA (sNDA) Decision (in: Articles)
Jan 10, 2012
Written by Mike Havrilla--Astex Pharma (NASDAQ:ASTX) is a cancer biotech w/ an approved drug that is marketed by Japan-based Eisai along with a summary of the Company's pending FDA and clinical trial catalysts below.
  Webinar Tuesday January 10th at 4:30pm EST (in: Articles)
Jan 9, 2012
  1/9/12 Clinical and Regulatory Calendar Summary (in: Articles)
Jan 9, 2012
  This Week's Watchlist 1/9/12 (in: Articles)
Jan 8, 2012
 
more articles >>